Back to Browse Journals » Vascular Health and Risk Management » Volume 5

The management of gestational diabetes

Authors N Wah Cheung

Published 15 January 2009 Volume 2009:5 Pages 153—164


Review by Single-blind

Peer reviewer comments 2

N Wah Cheung

Centre for Diabetes and Endocrinology Research, Westmead Hospital, and University of Sydney, NSW, Australia

Abstract: The incidence of gestational diabetes is increasing. As gestational diabetes is associated with adverse pregnancy outcomes, and has long-term implications for both mother and child, it is important that it is recognized and appropriately managed. This review will examine the pharmacological options for the management of gestational diabetes, as well as the evidence for blood glucose monitoring, dietary and exercise therapy. The medical management of gestational diabetes is still evolving, and recent randomized controlled trials have added considerably to our knowledge in this area. As insulin therapy is effective and safe, it is considered the gold standard of pharmacotherapy for gestational diabetes, against which other treatments have been compared. The current experience is that the short acting insulin analogs lispro and aspart are safe, but there are only limited data to support the use of long acting insulin analogs. There are randomized controlled trials which have demonstrated efficacy of the oral agents glyburide and metformin. Whilst short-term data have not demonstrated adverse effects of glyburide and metformin on the fetus, and they are increasingly being used in pregnancy, there remain long-term concerns regarding their potential for harm.

Keywords: gestational diabetes, insulin, oral antidiabetic agents, pregnancy, type 2 diabetes

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Linagliptin as add-on therapy to insulin for patients with type 2 diabetes

von Websky K, Reichetzeder C, Hocher B

Vascular Health and Risk Management 2013, 9:681-694

Published Date: 1 November 2013

Accuracy of the ankle-brachial index using the SCVL®, an arm and ankle automated device with synchronized cuffs, in a population with increased cardiovascular risk

Rosenbaum D, Rodriguez-Carranza S, Laroche P, Bruckert E, Giral P, Girerd X

Vascular Health and Risk Management 2012, 8:239-246

Published Date: 17 April 2012

The impact of diurnal fasting during Ramadan on the lipid profile, hs-CRP, and serum leptin in stable cardiac patients

Khafaji HARH, Bener A, Osman M, Al Merri A, Al Suwaidi J

Vascular Health and Risk Management 2012, 8:7-14

Published Date: 30 December 2011

Stentless aortic valve replacement: an update

Kobayashi J

Vascular Health and Risk Management 2011, 7:345-351

Published Date: 2 June 2011

New class of agents for treatment of hypertension: Focus on direct renin inhibition

Roberto Fogari, Annalisa Zoppi

Vascular Health and Risk Management 2010, 6:869-882

Published Date: 1 October 2010

Effectiveness of percutaneous laser revascularization therapy for refractory angina

Michael McGillion, Allison Cook, J Charles Victor, et al

Vascular Health and Risk Management 2010, 6:735-747

Published Date: 26 August 2010

The role of insulin detemir in overweight type 2 diabetes management

Yared N Demssie, Naveed Younis, Handrean Soran

Vascular Health and Risk Management 2009, 5:553-560

Published Date: 29 June 2009

Arterial stiffness in insulin resistance: The role of nitric oxide and angiotensin II receptors

Divina G Brillante, Anthony J O’Sullivan, Laurence G Howes

Vascular Health and Risk Management 2009, 5:73-78

Published Date: 4 December 2008

Effects of the vasodilating beta-blocker nebivolol on smoking-induced endothelial dysfunction in young healthy volunteers

André C Schmidt, Burkhard Flick, Elke Jahn, Peter Bramlage

Vascular Health and Risk Management 2008, 4:905-915

Published Date: 8 August 2008

Nonsteroidal antiinflammatory drugs are associated with increased aortic stiffness

Martin Claridge, Simon Hobbs, Clive Quick, Nick Day, Andrew Bradbury, Teun Wilmink

Vascular Health and Risk Management 2005, 1:149-153

Published Date: 15 July 2005